Dr Michael Chen, CEO and co‑founder of Nuclera, said: “Scientists are under pressure to progress increasingly complex membrane protein programs faster. By partnering with leadXpro, we can pair ...

Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific ...

Nigerian scientists achieve a major breakthrough in malaria drug research, depositing the first crystal structure of a key ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Despite significant progress in medicinal chemistry and life sciences research, drug discovery and development remain slow and expensive, taking on average approximately 15 years and US$2 billion to ...

AMES, Iowa – A tiny, solid sample of a drug, complete with active and inactive ingredients, spun at 50,000 revolutions per ...

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to ...

From antibiotic resistance to emerging viral threats, the global demand for new medicines is intensifying, yet traditional drug discovery pipelines remain slow and expensive. A new scientific review ...

Opportunities include enhanced device design, clinical adoption, value-based procurement, supply chain resilience, and agile contracting in diverse global markets. Implantable Drug Eluting Stent ...

Advances in machine learning and shape-memory polymers are enabling engineers to design for mechanical performance first and ...